The FDA has expanded its approval for Pfizer’s drug Xeljanz.
Currently, Xeljanz has been OK’d to treat rheumatoid and psoriatic arthritis. Now, it can be used for adult patients suffering from moderate to severe ulcerative colitis.
The company based its application for the approval on three successful controlled clinical trials that showed the drug the caused remission in about 17-18 percent of patients.
Pfizer anticipates that sales for Xeljanz could reach $2.16 billion in 2019.
Read the full Reuters report.